Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors

The use of allogeneic, pluripotent stem cell-derived immune cells for cancer immunotherapy has been the subject of recent research, including clinical trials. The use of pluripotent stem cells as the source for allogeneic immune cells facilitates stringent quality control of the final product, regar...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of hematology Vol. 114; no. 5; pp. 572 - 579
Main Authors Ueda, Tatsuki, Kaneko, Shin
Format Journal Article
LanguageEnglish
Published Singapore Springer Singapore 01.11.2021
Springer Nature B.V
Subjects
Animals
Antigens
Antigens, Neoplasm - immunology
Cancer immunotherapy
Chimeric antigen receptors
Clinical Studies as Topic
Clinical trials
Combined Modality Therapy
Drug Evaluation, Preclinical
Gene Expression
Genetic Engineering
Hematology
Humans
Immune system
Immunotherapy
Immunotherapy, Adoptive - adverse effects
Immunotherapy, Adoptive - methods
Induced Pluripotent Stem Cells - cytology
Induced Pluripotent Stem Cells - metabolism
Killer Cells, Natural - cytology
Killer Cells, Natural - immunology
Killer Cells, Natural - metabolism
Medicine
Medicine & Public Health
Natural killer cells
Neoplasms - etiology
Neoplasms - therapy
Oncology
Pluripotency
Product safety
Prognosis
Progress in Hematology
Quality control
Receptors
Receptors, Chimeric Antigen - genetics
Receptors, Chimeric Antigen - immunology
Solid tumors
Stem cells
Treatment Outcome
Tumors
Natural killer cell
Induced pluripotent stem cell
Chimeric antigen receptor
Immunotherapy
Online AccessGet full text

Cover

Abstract The use of allogeneic, pluripotent stem cell-derived immune cells for cancer immunotherapy has been the subject of recent research, including clinical trials. The use of pluripotent stem cells as the source for allogeneic immune cells facilitates stringent quality control of the final product, regarding efficacy, safety, and producibility. In this review, we have described the characteristics of natural killer (NK) cells from multiple cell sources, including pluripotent stem cells, the chimeric antigen receptor (CAR)-modification method and strategy for these NK cells, and the current and planned clinical trials of CAR-modified induced pluripotent stem cell-derived NK cells.
AbstractList The use of allogeneic, pluripotent stem cell-derived immune cells for cancer immunotherapy has been the subject of recent research, including clinical trials. The use of pluripotent stem cells as the source for allogeneic immune cells facilitates stringent quality control of the final product, regarding efficacy, safety, and producibility. In this review, we have described the characteristics of natural killer (NK) cells from multiple cell sources, including pluripotent stem cells, the chimeric antigen receptor (CAR)-modification method and strategy for these NK cells, and the current and planned clinical trials of CAR-modified induced pluripotent stem cell-derived NK cells.
The use of allogeneic, pluripotent stem cell-derived immune cells for cancer immunotherapy has been the subject of recent research, including clinical trials. The use of pluripotent stem cells as the source for allogeneic immune cells facilitates stringent quality control of the final product, regarding efficacy, safety, and producibility. In this review, we have described the characteristics of natural killer (NK) cells from multiple cell sources, including pluripotent stem cells, the chimeric antigen receptor (CAR)-modification method and strategy for these NK cells, and the current and planned clinical trials of CAR-modified induced pluripotent stem cell-derived NK cells.The use of allogeneic, pluripotent stem cell-derived immune cells for cancer immunotherapy has been the subject of recent research, including clinical trials. The use of pluripotent stem cells as the source for allogeneic immune cells facilitates stringent quality control of the final product, regarding efficacy, safety, and producibility. In this review, we have described the characteristics of natural killer (NK) cells from multiple cell sources, including pluripotent stem cells, the chimeric antigen receptor (CAR)-modification method and strategy for these NK cells, and the current and planned clinical trials of CAR-modified induced pluripotent stem cell-derived NK cells.
Author Ueda, Tatsuki
Kaneko, Shin
Author_xml – sequence: 1
  givenname: Tatsuki
  surname: Ueda
  fullname: Ueda, Tatsuki
  organization: Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, CiRA, Kyoto University
– sequence: 2
  givenname: Shin
  surname: Kaneko
  fullname: Kaneko, Shin
  email: kaneko.shin@cira.kyoto-u.ac.jp
  organization: Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, CiRA, Kyoto University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32705572$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtrHiEUhqWkNF8uf6CLInTTjY2XcS7LEnoJBLpJ1-Lo8aupo1N1SrvvD6_Jl1DIIgtROM9zOJ73BB3FFAGh14y-Z5QOF4VxNkpCOW1nkozIF2jHxl4SMQzdEdrRiUsiB0aP0Ukpt5SygXbDK3Qs-EClHPgO_b2KdjNg8Rq27NdUIVZcKizYQAjEQva_WjXqumUd8A8fAuT7WsF7iECWZL3zDakJw-81QynYfPdLEw3WsfpG4QwG1poyqTrvofq4xyUF36RtSbmcoZdOhwLnD_cp-vbp483lF3L99fPV5YdrYrqOVSKEsL2DaXKO9UY6B6zjzoKR2nCpOz1Zalh7ODdZoN0497ObYNZOzG0tozhF7w5915x-blCqWny5-4uOkLaieMcHQTmf-oa-fYLepi3HNp3icqRtwaJnjXrzQG3zAlat2S86_1GP-23AeABMTqVkcMr4qqtPsWbtg2JU3UWpDlGqFqW6j1LJpvIn6mP3ZyVxkEqD4x7y_7Gfsf4BlR-z_A
CitedBy_id crossref_primary_10_3390_biomedicines10112912
crossref_primary_10_3389_fimmu_2024_1337557
crossref_primary_10_1111_cpr_13425
crossref_primary_10_3390_biom14081035
crossref_primary_10_3390_nano13212873
crossref_primary_10_3389_fimmu_2020_611163
crossref_primary_10_1016_j_ejmech_2022_114920
Cites_doi 10.1182/blood-2008-06-165225
10.1016/S0140-6736(05)67813-0
10.1038/nri.2016.80
10.1182/blood-2002-10-3293
10.1056/NEJMoa1910607
10.1158/2159-8290.CD-13-0985
10.1038/cmi.2015.57
10.1182/blood-2012-10-461442
10.1038/ni0508-477
10.1016/j.smim.2008.04.001
10.1056/NEJMoa1407222
10.1038/cmi.2015.42
10.1038/s41598-019-55239-y
10.1016/j.cell.2007.11.019
10.1016/j.ymthe.2017.06.012
10.4049/jimmunol.175.8.5095
10.1038/s41591-018-0041-7
10.1182/blood-2017-12-823757
10.1038/nbt0708-739
10.1038/cmi.2014.104
10.1016/j.ymthe.2016.10.016
10.1016/j.cell.2006.07.024
10.1038/bmt.2008.380
10.1016/j.cell.2018.10.014
10.1182/blood-2010-04-281675
10.1126/science.1151526
10.1159/000327014
10.1016/j.bbmt.2015.12.028
10.1182/blood.V97.1.14
10.4049/jimmunol.181.9.6010
10.1200/JCO.1989.7.2.250
10.1126/science.1103478
10.1016/j.stemcr.2017.10.020
10.1016/j.matbio.2013.10.009
10.5966/sctm.2012-0084
10.1002/eji.201444464
10.1038/nbt.3860
10.1038/leu.2017.226
10.1158/0008-5472.CAN-14-0697
10.1038/aps.2017.125
10.1038/cmi.2014.91
10.1007/s00262-014-1629-5
10.1182/blood-2004-07-2974
10.1016/j.stemcr.2014.01.014
10.1002/stem.2230
10.1073/pnas.90.2.720
10.1038/gt.2013.19
10.1084/jem.20051511
10.1002/1097-0142(19940315)73:6<1731::AID-CNCR2820730630>3.0.CO;2-H
10.1200/JCO.2009.24.4590
10.1111/imr.12325
10.1016/S1470-2045(18)30148-7
10.1042/BST20150249
10.1038/cmi.2015.07
10.3389/fimmu.2017.00533
10.3390/ijms20112839
10.1038/ncomms8458
10.1371/journal.pone.0008975
10.1126/scitranslmed.3002842
10.1371/journal.pone.0007076
10.4161/onci.28147
10.3389/fimmu.2017.01124
10.1371/journal.pone.0009221
10.1038/s41419-018-0278-6
10.1111/cas.14374
ContentType Journal Article
Copyright Japanese Society of Hematology 2020
2020. Japanese Society of Hematology.
Japanese Society of Hematology 2020.
Copyright_xml – notice: Japanese Society of Hematology 2020
– notice: 2020. Japanese Society of Hematology.
– notice: Japanese Society of Hematology 2020.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7T5
7T7
7TM
7X7
7XB
88E
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
C1K
CCPQU
FR3
FYUFA
GHDGH
H94
K9.
KB0
M0S
M1P
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s12185-020-02951-5
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One Community College
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni)
Medical Database
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Technology Research Database
ProQuest One Academic Middle East (New)
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
Technology Research Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1865-3774
EndPage 579
ExternalDocumentID 32705572
10_1007_s12185_020_02951_5
Genre Journal Article
Review
GrantInformation_xml – fundername: Japan Agency for Medical Research and Development
  grantid: Practical Research for Innovative Cancer Control
  funderid: http://dx.doi.org/10.13039/100009619
– fundername: Japan Agency for Medical Research and Development
  grantid: Practical Research for Innovative Cancer Control
GroupedDBID ---
--K
-5E
-5G
-BR
-EM
-Y2
-~C
.55
.86
.VR
06C
06D
0R~
0VY
1B1
1N0
203
29J
29~
2J2
2JN
2JY
2KG
2KM
2LR
2VQ
2~H
30V
3V.
4.4
406
408
40D
40E
53G
5GY
5VS
67Z
6NX
7RV
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABDZT
ABECU
ABFTV
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACDTI
ACGFO
ACGFS
ACHSB
ACHVE
ACHXU
ACIHN
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACREN
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZKW
AEAQA
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BDATZ
BENPR
BGNMA
BKEYQ
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
EN4
ESBYG
EX3
F5P
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
H13
HF~
HG5
HG6
HLICF
HMCUK
HMJXF
HRMNR
HZ~
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JZLTJ
KOV
KPH
LLZTM
M1P
M41
M4Y
MA-
N9A
NAPCQ
NPVJJ
NQ-
NQJWS
NU0
O9-
O93
O9I
O9J
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
Q2X
QOR
QOS
R89
R9I
RIG
ROL
RPX
RPZ
RSV
S16
S1Z
S27
S37
S3B
SAP
SDH
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UDS
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WJK
WK8
WOW
X7M
YLTOR
Z45
Z7U
Z81
Z82
Z87
ZMTXR
ZOVNA
ZXP
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
AEZWR
AFDZB
AFHIU
AFOHR
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7T7
7TM
7XB
8FD
8FK
ABRTQ
C1K
FR3
H94
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c441t-333d6fe99ff16c5ffe142fdec5ac25a4a9d0c15a4ff9de048b6bf9ebaf3b18683
IEDL.DBID U2A
ISSN 0925-5710
1865-3774
IngestDate Mon Jul 21 09:23:32 EDT 2025
Sat Jul 26 02:17:11 EDT 2025
Thu Apr 03 07:03:10 EDT 2025
Thu Apr 24 23:00:26 EDT 2025
Tue Jul 01 03:48:00 EDT 2025
Fri Feb 21 02:47:10 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Natural killer cell
Induced pluripotent stem cell
Chimeric antigen receptor
Immunotherapy
Language English
License 2020. Japanese Society of Hematology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c441t-333d6fe99ff16c5ffe142fdec5ac25a4a9d0c15a4ff9de048b6bf9ebaf3b18683
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
PMID 32705572
PQID 2580377361
PQPubID 55446
PageCount 8
ParticipantIDs proquest_miscellaneous_2427302296
proquest_journals_2580377361
pubmed_primary_32705572
crossref_citationtrail_10_1007_s12185_020_02951_5
crossref_primary_10_1007_s12185_020_02951_5
springer_journals_10_1007_s12185_020_02951_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-11-01
PublicationDateYYYYMMDD 2021-11-01
PublicationDate_xml – month: 11
  year: 2021
  text: 2021-11-01
  day: 01
PublicationDecade 2020
PublicationPlace Singapore
PublicationPlace_xml – name: Singapore
– name: Japan
– name: Tokyo
PublicationTitle International journal of hematology
PublicationTitleAbbrev Int J Hematol
PublicationTitleAlternate Int J Hematol
PublicationYear 2021
Publisher Springer Singapore
Springer Nature B.V
Publisher_xml – name: Springer Singapore
– name: Springer Nature B.V
References Wennerberg, Kremer, Childs, Lundqvist (CR58) 2014; 64
Fisher (CR53) 1989; 7
Hu, Tian, Zhang (CR2) 2018; 39
Mao (CR66) 2016; 13
Giavridis, Van Der Stegen, Eyquem, Hamieh, Piersigilli, Sadelain (CR13) 2018; 24
Goodridge, Önfelt, Malmberg (CR5) 2015; 267
Shaffer (CR10) 2016; 22
Romee (CR50) 2018; 131
Sun, Sun, Zhang, Tian (CR7) 2015; 12
Liu (CR40) 2018; 32
Miller (CR8) 2005; 105
Béziat (CR38) 2013; 121
Knorr (CR26) 2013; 2
Zeng, Tang, Toh, Wang (CR36) 2017; 9
Rekik, Belhadj Hmida, Ben Hmid, Zamali, Kammoun, Ben (CR68) 2015; 12
CR3
Liu (CR15) 2020; 382
Takahashi, Yamanaka (CR20) 2006; 126
Herrera (CR18) 2019; 9
Mohammed (CR70) 2017; 25
Fehniger, Caligiuri (CR48) 2001; 97
Li, Hermanson, Moriarity, Kaufman (CR41) 2018; 23
Stewart, Sanderson (CR64) 2014; 35
CR44
Nguyen (CR33) 2009; 43
CR43
CR42
Béziat (CR39) 2014; 44
Rubnitz (CR9) 2010; 28
Taylor, Bolton, Pocock, Sharples, Pedersen, Bradley (CR29) 2005; 366
Nakatsuji, Nakajima, Tokunaga (CR30) 2008; 26
Zhang (CR69) 2015; 12
Kärre (CR6) 2008; 9
CR19
CR17
CR16
Beider (CR51) 2003; 102
CR59
Speiser, Ho, Verdeil (CR65) 2016; 16
Wrangle (CR49) 2018; 19
CR56
CR11
Maude (CR12) 2014; 371
Hermanson (CR37) 2016; 34
CR55
Woll (CR28) 2009; 113
Valamehr (CR25) 2014; 2
Nishio (CR61) 2014; 74
Woll, Martin, Miller, Kaufman (CR27) 2005; 175
Krneta, Gillgrass, Chew, Ashkar (CR67) 2016; 13
Sampson, Archer, Mitchell, Heimberger, Bigner (CR45) 2008; 20
Ghiringhelli (CR46) 2005; 202
Vivier, Nunès, Vély (CR4) 2004; 306
André (CR34) 2018; 175
Takahashi (CR21) 2007; 131
Yu, Vodyanik, Smuga-Otto, Antosiewicz-Bourget, Frane, Tian, Nie, Jonsdottir, Ruotti, Stewart, Slukvin (CR22) 2007; 318
CR24
Hirata (CR31) 2017; 35
Groth, Klöss, Pogge Von Strandmann, Koehl, Koch (CR52) 2011; 3
CR23
Björkström (CR35) 2010; 116
Pockaj (CR54) 1994; 73
Whilding, Vallath, Maher (CR62) 2016; 44
Wang (CR63) 2013; 20
Rezvani, Rouce, Liu, Shpall (CR14) 2017; 25
CR60
Fauriat (CR32) 2008; 181
Melero, Rouzaut, Motz, Coukos (CR57) 2014; 4
Eshhar, Waks, Gross, Schindler (CR1) 1993; 90
Waldmann, Dubois, Tagaya (CR47) 2001; 14
J Zeng (2951_CR36) 2017; 9
Y Hu (2951_CR2) 2018; 39
2951_CR3
V Béziat (2951_CR38) 2013; 121
F Ghiringhelli (2951_CR46) 2005; 202
B Valamehr (2951_CR25) 2014; 2
E Liu (2951_CR40) 2018; 32
S Zhang (2951_CR69) 2015; 12
Y Mao (2951_CR66) 2016; 13
C Fauriat (2951_CR32) 2008; 181
T Krneta (2951_CR67) 2016; 13
K Kärre (2951_CR6) 2008; 9
N Nakatsuji (2951_CR30) 2008; 26
JH Sampson (2951_CR45) 2008; 20
TA Waldmann (2951_CR47) 2001; 14
K Rezvani (2951_CR14) 2017; 25
B Fisher (2951_CR53) 1989; 7
2951_CR60
JE Rubnitz (2951_CR9) 2010; 28
TA Fehniger (2951_CR48) 2001; 97
K Takahashi (2951_CR21) 2007; 131
2951_CR23
2951_CR24
BC Shaffer (2951_CR10) 2016; 22
I Melero (2951_CR57) 2014; 4
R Romee (2951_CR50) 2018; 131
DA Knorr (2951_CR26) 2013; 2
PS Woll (2951_CR27) 2005; 175
L Herrera (2951_CR18) 2019; 9
JP Goodridge (2951_CR5) 2015; 267
N Nishio (2951_CR61) 2014; 74
J Yu (2951_CR22) 2007; 318
DE Speiser (2951_CR65) 2016; 16
LM Whilding (2951_CR62) 2016; 44
2951_CR11
2951_CR55
PS Woll (2951_CR28) 2009; 113
K Takahashi (2951_CR20) 2006; 126
2951_CR59
2951_CR56
JM Wrangle (2951_CR49) 2018; 19
E Wennerberg (2951_CR58) 2014; 64
2951_CR19
2951_CR16
E Vivier (2951_CR4) 2004; 306
2951_CR17
A Groth (2951_CR52) 2011; 3
SL Maude (2951_CR12) 2014; 371
S Nguyen (2951_CR33) 2009; 43
BA Pockaj (2951_CR54) 1994; 73
C Sun (2951_CR7) 2015; 12
JS Miller (2951_CR8) 2005; 105
T Giavridis (2951_CR13) 2018; 24
DL Hermanson (2951_CR37) 2016; 34
Y Li (2951_CR41) 2018; 23
W Wang (2951_CR63) 2013; 20
S Mohammed (2951_CR70) 2017; 25
RK Hirata (2951_CR31) 2017; 35
2951_CR43
R Rekik (2951_CR68) 2015; 12
P André (2951_CR34) 2018; 175
2951_CR44
2951_CR42
CJ Taylor (2951_CR29) 2005; 366
K Beider (2951_CR51) 2003; 102
NK Björkström (2951_CR35) 2010; 116
V Béziat (2951_CR39) 2014; 44
MD Stewart (2951_CR64) 2014; 35
E Liu (2951_CR15) 2020; 382
Z Eshhar (2951_CR1) 1993; 90
References_xml – volume: 113
  start-page: 6094
  issue: 24
  year: 2009
  end-page: 6101
  ident: CR28
  article-title: Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity
  publication-title: Blood
  doi: 10.1182/blood-2008-06-165225
– volume: 366
  start-page: 2019
  issue: 9502
  year: 2005
  end-page: 2025
  ident: CR29
  article-title: Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)67813-0
– volume: 16
  start-page: 599
  issue: 10
  year: 2016
  end-page: 611
  ident: CR65
  article-title: Regulatory circuits of T cell function in cancer
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri.2016.80
– volume: 102
  start-page: 1951
  issue: 6
  year: 2003
  end-page: 1958
  ident: CR51
  article-title: Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice
  publication-title: Blood
  doi: 10.1182/blood-2002-10-3293
– ident: CR16
– volume: 382
  start-page: 545
  issue: 6
  year: 2020
  end-page: 553
  ident: CR15
  article-title: Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1910607
– volume: 23
  start-page: 181.e5
  issue: 2
  year: 2018
  end-page: 192.e5
  ident: CR41
  article-title: Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity
  publication-title: Cell Stem Cell
– volume: 4
  start-page: 522
  issue: 5
  year: 2014
  end-page: 526
  ident: CR57
  article-title: T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-13-0985
– volume: 12
  start-page: 580
  issue: 5
  year: 2015
  end-page: 591
  ident: CR69
  article-title: Analysis of CD8 + Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2015.57
– volume: 121
  start-page: 4703
  issue: 23
  year: 2013
  end-page: 4707
  ident: CR38
  article-title: Influence of KIR gene copy number on natural killer cell education
  publication-title: Blood
  doi: 10.1182/blood-2012-10-461442
– volume: 9
  start-page: 477
  issue: 5
  year: 2008
  end-page: 480
  ident: CR6
  article-title: Natural killer cell recognition of missing self
  publication-title: Nat Immunol
  doi: 10.1038/ni0508-477
– volume: 20
  start-page: 267
  issue: 5
  year: 2008
  end-page: 275
  ident: CR45
  article-title: Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
  publication-title: Semin Immunol
  doi: 10.1016/j.smim.2008.04.001
– ident: CR42
– volume: 371
  start-page: 1507
  issue: 16
  year: 2014
  end-page: 1517
  ident: CR12
  article-title: Chimeric antigen receptor T cells for sustained remissions in leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1407222
– ident: CR19
– volume: 13
  start-page: 628
  issue: 5
  year: 2016
  end-page: 639
  ident: CR67
  article-title: The breast tumor microenvironment alters the phenotype and function of natural killer cells
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2015.42
– volume: 9
  start-page: 1
  issue: 1
  year: 2019
  end-page: 10
  ident: CR18
  article-title: Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-55239-y
– volume: 131
  start-page: 861
  issue: 5
  year: 2007
  end-page: 872
  ident: CR21
  article-title: Induction of pluripotent stem cells from adult human fibroblasts by defined factors
  publication-title: Cell
  doi: 10.1016/j.cell.2007.11.019
– volume: 25
  start-page: 1769
  issue: 8
  year: 2017
  end-page: 1781
  ident: CR14
  article-title: Engineering natural killer cells for cancer immunotherapy
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2017.06.012
– volume: 175
  start-page: 5095
  issue: 8
  year: 2005
  end-page: 5103
  ident: CR27
  article-title: Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity
  publication-title: J Immunol
  doi: 10.4049/jimmunol.175.8.5095
– volume: 24
  start-page: 731
  issue: 6
  year: 2018
  end-page: 738
  ident: CR13
  article-title: CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0041-7
– ident: CR11
– volume: 131
  start-page: 2515
  issue: 23
  year: 2018
  end-page: 2527
  ident: CR50
  article-title: First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
  publication-title: Blood
  doi: 10.1182/blood-2017-12-823757
– ident: CR60
– volume: 26
  start-page: 739
  issue: 7
  year: 2008
  end-page: 740
  ident: CR30
  article-title: HLA-haplotype banking and iPS cells
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt0708-739
– volume: 12
  start-page: 648
  issue: 5
  year: 2015
  end-page: 649
  ident: CR68
  article-title: PD-1 induction through TCR activation is partially regulated by endogenous TGF-β
  publication-title: Cell Mol Immunol.
  doi: 10.1038/cmi.2014.104
– volume: 25
  start-page: 249
  issue: 1
  year: 2017
  end-page: 258
  ident: CR70
  article-title: Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2016.10.016
– volume: 126
  start-page: 663
  year: 2006
  end-page: 676
  ident: CR20
  article-title: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors
  publication-title: Cell
  doi: 10.1016/j.cell.2006.07.024
– volume: 43
  start-page: 693
  issue: 9
  year: 2009
  end-page: 699
  ident: CR33
  article-title: HLA-E upregulation on IFN-γ-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT
  publication-title: Bone Marrow Transpl
  doi: 10.1038/bmt.2008.380
– volume: 175
  start-page: 1731.e13
  issue: 7
  year: 2018
  end-page: 1743.e13
  ident: CR34
  article-title: Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells
  publication-title: Cell
  doi: 10.1016/j.cell.2018.10.014
– volume: 116
  start-page: 3853
  issue: 19
  year: 2010
  end-page: 3864
  ident: CR35
  article-title: Expression patterns of NKG2A, KIR, and CD57 define a process of CD56 dim NK-cell differentiation uncoupled from NK-cell education
  publication-title: Blood
  doi: 10.1182/blood-2010-04-281675
– volume: 318
  start-page: 1917
  issue: 21
  year: 2007
  end-page: 1920
  ident: CR22
  article-title: Induced pluripotent stem cell lines derived from human somatic cells
  publication-title: Science
  doi: 10.1126/science.1151526
– volume: 3
  start-page: 344
  issue: 4
  year: 2011
  end-page: 354
  ident: CR52
  article-title: Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance
  publication-title: J Innate Immun
  doi: 10.1159/000327014
– volume: 22
  start-page: 705
  issue: 4
  year: 2016
  end-page: 709
  ident: CR10
  article-title: Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation
  publication-title: Biol Blood Marrow Transpl
  doi: 10.1016/j.bbmt.2015.12.028
– volume: 97
  start-page: 14
  issue: 1
  year: 2001
  end-page: 32
  ident: CR48
  article-title: Interleukin 15: biology and relevance to human disease
  publication-title: Blood
  doi: 10.1182/blood.V97.1.14
– volume: 181
  start-page: 6010
  issue: 9
  year: 2008
  end-page: 6019
  ident: CR32
  article-title: Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype
  publication-title: J. Immunol
  doi: 10.4049/jimmunol.181.9.6010
– volume: 7
  start-page: 250
  issue: 2
  year: 1989
  end-page: 261
  ident: CR53
  article-title: Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1989.7.2.250
– ident: CR43
– volume: 306
  start-page: 1517
  issue: 5701
  year: 2004
  end-page: 1519
  ident: CR4
  article-title: Natural killer cell signaling pathways
  publication-title: Science
  doi: 10.1126/science.1103478
– volume: 9
  start-page: 1796
  issue: 6
  year: 2017
  end-page: 1812
  ident: CR36
  article-title: Generation of ‘off-the-shelf’ natural killer cells from peripheral blood cell-derived induced pluripotent stem cells
  publication-title: Stem Cell Rep
  doi: 10.1016/j.stemcr.2017.10.020
– volume: 35
  start-page: 56
  year: 2014
  end-page: 59
  ident: CR64
  article-title: Heparan sulfate in the nucleus and its control of cellular functions
  publication-title: Matrix Biol
  doi: 10.1016/j.matbio.2013.10.009
– volume: 2
  start-page: 274
  issue: 4
  year: 2013
  end-page: 283
  ident: CR26
  article-title: Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy
  publication-title: Stem Cells Transl Med
  doi: 10.5966/sctm.2012-0084
– volume: 44
  start-page: 2192
  issue: 7
  year: 2014
  end-page: 2196
  ident: CR39
  article-title: Tracing dynamic expansion of human NK-cell subsets by high-resolution analysis of KIR repertoires and cellular differentiation
  publication-title: Eur J Immunol
  doi: 10.1002/eji.201444464
– volume: 35
  start-page: 765
  issue: 8
  year: 2017
  end-page: 772
  ident: CR31
  article-title: HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3860
– volume: 32
  start-page: 520
  issue: 2
  year: 2018
  end-page: 531
  ident: CR40
  article-title: Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
  publication-title: Leukemia
  doi: 10.1038/leu.2017.226
– volume: 74
  start-page: 5195
  issue: 18
  year: 2014
  end-page: 5205
  ident: CR61
  article-title: Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-0697
– volume: 39
  start-page: 167
  issue: 2
  year: 2018
  end-page: 176
  ident: CR2
  article-title: Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/aps.2017.125
– volume: 12
  start-page: 292
  issue: 3
  year: 2015
  end-page: 302
  ident: CR7
  article-title: NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2014.91
– volume: 64
  start-page: 225
  issue: 2
  year: 2014
  end-page: 235
  ident: CR58
  article-title: CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-014-1629-5
– volume: 105
  start-page: 3051
  issue: 8
  year: 2005
  end-page: 3057
  ident: CR8
  article-title: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
  publication-title: Blood
  doi: 10.1182/blood-2004-07-2974
– ident: CR56
– volume: 2
  start-page: 366
  issue: 3
  year: 2014
  end-page: 381
  ident: CR25
  article-title: Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells
  publication-title: Stem Cell Rep
  doi: 10.1016/j.stemcr.2014.01.014
– volume: 34
  start-page: 93
  issue: 1
  year: 2016
  end-page: 101
  ident: CR37
  article-title: Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer
  publication-title: Stem Cells
  doi: 10.1002/stem.2230
– ident: CR23
– ident: CR44
– volume: 90
  start-page: 720
  issue: 2
  year: 1993
  end-page: 724
  ident: CR1
  article-title: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.90.2.720
– volume: 20
  start-page: 970
  issue: 10
  year: 2013
  end-page: 978
  ident: CR63
  article-title: Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency
  publication-title: Gene Ther
  doi: 10.1038/gt.2013.19
– volume: 14
  start-page: 105
  issue: 2
  year: 2001
  end-page: 110
  ident: CR47
  article-title: Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy
  publication-title: Immunity
– ident: CR3
– volume: 202
  start-page: 1075
  issue: 8
  year: 2005
  end-page: 1085
  ident: CR46
  article-title: CD4 + CD25 + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner
  publication-title: J Exp Med
  doi: 10.1084/jem.20051511
– volume: 73
  start-page: 1731
  issue: 6
  year: 1994
  end-page: 1737
  ident: CR54
  article-title: Localization of 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response
  publication-title: Cancer
  doi: 10.1002/1097-0142(19940315)73:6<1731::AID-CNCR2820730630>3.0.CO;2-H
– ident: CR17
– volume: 28
  start-page: 955
  issue: 6
  year: 2010
  end-page: 959
  ident: CR9
  article-title: NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.24.4590
– ident: CR55
– ident: CR59
– volume: 267
  start-page: 197
  issue: 1
  year: 2015
  end-page: 213
  ident: CR5
  article-title: Newtonian cell interactions shape natural killer cell education
  publication-title: Immunol Rev
  doi: 10.1111/imr.12325
– volume: 19
  start-page: 694
  issue: 5
  year: 2018
  end-page: 704
  ident: CR49
  article-title: ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30148-7
– ident: CR24
– volume: 44
  start-page: 349
  issue: 2
  year: 2016
  end-page: 355
  ident: CR62
  article-title: The integrin αvβ6: a novel target for CAR T-cell immunotherapy?
  publication-title: Biochem Soc Trans
  doi: 10.1042/BST20150249
– volume: 13
  start-page: 217
  issue: 2
  year: 2016
  end-page: 228
  ident: CR66
  article-title: A new effect of IL-4 on human γδ cells: promoting regulatory Vδ1 T cells via IL-10 production and inhibiting function of Vδ2 T cells
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2015.07
– ident: 2951_CR16
  doi: 10.3389/fimmu.2017.00533
– ident: 2951_CR17
  doi: 10.3390/ijms20112839
– volume: 20
  start-page: 267
  issue: 5
  year: 2008
  ident: 2951_CR45
  publication-title: Semin Immunol
  doi: 10.1016/j.smim.2008.04.001
– volume: 22
  start-page: 705
  issue: 4
  year: 2016
  ident: 2951_CR10
  publication-title: Biol Blood Marrow Transpl
  doi: 10.1016/j.bbmt.2015.12.028
– volume: 35
  start-page: 765
  issue: 8
  year: 2017
  ident: 2951_CR31
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3860
– volume: 116
  start-page: 3853
  issue: 19
  year: 2010
  ident: 2951_CR35
  publication-title: Blood
  doi: 10.1182/blood-2010-04-281675
– volume: 2
  start-page: 366
  issue: 3
  year: 2014
  ident: 2951_CR25
  publication-title: Stem Cell Rep
  doi: 10.1016/j.stemcr.2014.01.014
– volume: 44
  start-page: 2192
  issue: 7
  year: 2014
  ident: 2951_CR39
  publication-title: Eur J Immunol
  doi: 10.1002/eji.201444464
– volume: 181
  start-page: 6010
  issue: 9
  year: 2008
  ident: 2951_CR32
  publication-title: J. Immunol
  doi: 10.4049/jimmunol.181.9.6010
– ident: 2951_CR60
  doi: 10.1038/ncomms8458
– volume: 121
  start-page: 4703
  issue: 23
  year: 2013
  ident: 2951_CR38
  publication-title: Blood
  doi: 10.1182/blood-2012-10-461442
– volume: 113
  start-page: 6094
  issue: 24
  year: 2009
  ident: 2951_CR28
  publication-title: Blood
  doi: 10.1182/blood-2008-06-165225
– volume: 12
  start-page: 292
  issue: 3
  year: 2015
  ident: 2951_CR7
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2014.91
– ident: 2951_CR23
  doi: 10.1371/journal.pone.0008975
– volume: 43
  start-page: 693
  issue: 9
  year: 2009
  ident: 2951_CR33
  publication-title: Bone Marrow Transpl
  doi: 10.1038/bmt.2008.380
– volume: 267
  start-page: 197
  issue: 1
  year: 2015
  ident: 2951_CR5
  publication-title: Immunol Rev
  doi: 10.1111/imr.12325
– ident: 2951_CR11
  doi: 10.1126/scitranslmed.3002842
– ident: 2951_CR24
  doi: 10.1371/journal.pone.0007076
– volume: 34
  start-page: 93
  issue: 1
  year: 2016
  ident: 2951_CR37
  publication-title: Stem Cells
  doi: 10.1002/stem.2230
– ident: 2951_CR3
  doi: 10.4161/onci.28147
– volume: 64
  start-page: 225
  issue: 2
  year: 2014
  ident: 2951_CR58
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-014-1629-5
– volume: 19
  start-page: 694
  issue: 5
  year: 2018
  ident: 2951_CR49
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30148-7
– volume: 39
  start-page: 167
  issue: 2
  year: 2018
  ident: 2951_CR2
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/aps.2017.125
– volume: 126
  start-page: 663
  year: 2006
  ident: 2951_CR20
  publication-title: Cell
  doi: 10.1016/j.cell.2006.07.024
– ident: 2951_CR56
  doi: 10.3389/fimmu.2017.01124
– volume: 44
  start-page: 349
  issue: 2
  year: 2016
  ident: 2951_CR62
  publication-title: Biochem Soc Trans
  doi: 10.1042/BST20150249
– volume: 23
  start-page: 181.e5
  issue: 2
  year: 2018
  ident: 2951_CR41
  publication-title: Cell Stem Cell
– volume: 366
  start-page: 2019
  issue: 9502
  year: 2005
  ident: 2951_CR29
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)67813-0
– ident: 2951_CR42
– ident: 2951_CR55
  doi: 10.3389/fimmu.2017.01124
– volume: 202
  start-page: 1075
  issue: 8
  year: 2005
  ident: 2951_CR46
  publication-title: J Exp Med
  doi: 10.1084/jem.20051511
– volume: 131
  start-page: 2515
  issue: 23
  year: 2018
  ident: 2951_CR50
  publication-title: Blood
  doi: 10.1182/blood-2017-12-823757
– volume: 20
  start-page: 970
  issue: 10
  year: 2013
  ident: 2951_CR63
  publication-title: Gene Ther
  doi: 10.1038/gt.2013.19
– volume: 35
  start-page: 56
  year: 2014
  ident: 2951_CR64
  publication-title: Matrix Biol
  doi: 10.1016/j.matbio.2013.10.009
– volume: 13
  start-page: 217
  issue: 2
  year: 2016
  ident: 2951_CR66
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2015.07
– volume: 97
  start-page: 14
  issue: 1
  year: 2001
  ident: 2951_CR48
  publication-title: Blood
  doi: 10.1182/blood.V97.1.14
– ident: 2951_CR19
  doi: 10.1371/journal.pone.0009221
– ident: 2951_CR59
  doi: 10.1038/ncomms8458
– volume: 371
  start-page: 1507
  issue: 16
  year: 2014
  ident: 2951_CR12
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1407222
– ident: 2951_CR44
  doi: 10.1038/s41419-018-0278-6
– volume: 16
  start-page: 599
  issue: 10
  year: 2016
  ident: 2951_CR65
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri.2016.80
– volume: 12
  start-page: 648
  issue: 5
  year: 2015
  ident: 2951_CR68
  publication-title: Cell Mol Immunol.
  doi: 10.1038/cmi.2014.104
– volume: 74
  start-page: 5195
  issue: 18
  year: 2014
  ident: 2951_CR61
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-0697
– volume: 9
  start-page: 1
  issue: 1
  year: 2019
  ident: 2951_CR18
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-55239-y
– ident: 2951_CR43
  doi: 10.1111/cas.14374
– volume: 13
  start-page: 628
  issue: 5
  year: 2016
  ident: 2951_CR67
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2015.42
– volume: 318
  start-page: 1917
  issue: 21
  year: 2007
  ident: 2951_CR22
  publication-title: Science
  doi: 10.1126/science.1151526
– volume: 90
  start-page: 720
  issue: 2
  year: 1993
  ident: 2951_CR1
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.90.2.720
– volume: 131
  start-page: 861
  issue: 5
  year: 2007
  ident: 2951_CR21
  publication-title: Cell
  doi: 10.1016/j.cell.2007.11.019
– volume: 306
  start-page: 1517
  issue: 5701
  year: 2004
  ident: 2951_CR4
  publication-title: Science
  doi: 10.1126/science.1103478
– volume: 9
  start-page: 477
  issue: 5
  year: 2008
  ident: 2951_CR6
  publication-title: Nat Immunol
  doi: 10.1038/ni0508-477
– volume: 2
  start-page: 274
  issue: 4
  year: 2013
  ident: 2951_CR26
  publication-title: Stem Cells Transl Med
  doi: 10.5966/sctm.2012-0084
– volume: 73
  start-page: 1731
  issue: 6
  year: 1994
  ident: 2951_CR54
  publication-title: Cancer
  doi: 10.1002/1097-0142(19940315)73:6<1731::AID-CNCR2820730630>3.0.CO;2-H
– volume: 175
  start-page: 1731.e13
  issue: 7
  year: 2018
  ident: 2951_CR34
  publication-title: Cell
  doi: 10.1016/j.cell.2018.10.014
– volume: 105
  start-page: 3051
  issue: 8
  year: 2005
  ident: 2951_CR8
  publication-title: Blood
  doi: 10.1182/blood-2004-07-2974
– volume: 25
  start-page: 1769
  issue: 8
  year: 2017
  ident: 2951_CR14
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2017.06.012
– volume: 9
  start-page: 1796
  issue: 6
  year: 2017
  ident: 2951_CR36
  publication-title: Stem Cell Rep
  doi: 10.1016/j.stemcr.2017.10.020
– volume: 12
  start-page: 580
  issue: 5
  year: 2015
  ident: 2951_CR69
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2015.57
– volume: 32
  start-page: 520
  issue: 2
  year: 2018
  ident: 2951_CR40
  publication-title: Leukemia
  doi: 10.1038/leu.2017.226
– volume: 4
  start-page: 522
  issue: 5
  year: 2014
  ident: 2951_CR57
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-13-0985
– volume: 25
  start-page: 249
  issue: 1
  year: 2017
  ident: 2951_CR70
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2016.10.016
– volume: 24
  start-page: 731
  issue: 6
  year: 2018
  ident: 2951_CR13
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0041-7
– volume: 3
  start-page: 344
  issue: 4
  year: 2011
  ident: 2951_CR52
  publication-title: J Innate Immun
  doi: 10.1159/000327014
– volume: 26
  start-page: 739
  issue: 7
  year: 2008
  ident: 2951_CR30
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt0708-739
– volume: 7
  start-page: 250
  issue: 2
  year: 1989
  ident: 2951_CR53
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1989.7.2.250
– volume: 28
  start-page: 955
  issue: 6
  year: 2010
  ident: 2951_CR9
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.24.4590
– volume: 175
  start-page: 5095
  issue: 8
  year: 2005
  ident: 2951_CR27
  publication-title: J Immunol
  doi: 10.4049/jimmunol.175.8.5095
– volume: 14
  start-page: 105
  issue: 2
  year: 2001
  ident: 2951_CR47
  publication-title: Immunity
– volume: 102
  start-page: 1951
  issue: 6
  year: 2003
  ident: 2951_CR51
  publication-title: Blood
  doi: 10.1182/blood-2002-10-3293
– volume: 382
  start-page: 545
  issue: 6
  year: 2020
  ident: 2951_CR15
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1910607
SSID ssj0017047
Score 2.3498077
SecondaryResourceType review_article
Snippet The use of allogeneic, pluripotent stem cell-derived immune cells for cancer immunotherapy has been the subject of recent research, including clinical trials....
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 572
SubjectTerms Animals
Antigens
Antigens, Neoplasm - immunology
Cancer immunotherapy
Chimeric antigen receptors
Clinical Studies as Topic
Clinical trials
Combined Modality Therapy
Drug Evaluation, Preclinical
Gene Expression
Genetic Engineering
Hematology
Humans
Immune system
Immunotherapy
Immunotherapy, Adoptive - adverse effects
Immunotherapy, Adoptive - methods
Induced Pluripotent Stem Cells - cytology
Induced Pluripotent Stem Cells - metabolism
Killer Cells, Natural - cytology
Killer Cells, Natural - immunology
Killer Cells, Natural - metabolism
Medicine
Medicine & Public Health
Natural killer cells
Neoplasms - etiology
Neoplasms - therapy
Oncology
Pluripotency
Product safety
Prognosis
Progress in Hematology
Quality control
Receptors
Receptors, Chimeric Antigen - genetics
Receptors, Chimeric Antigen - immunology
Solid tumors
Stem cells
Treatment Outcome
Tumors
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3faxQxEA61BfFFqq26tUoE39rgZpPsmqdSxFKE9qmFe1s2yQQP29uzt1f8A_zDO5PN3SHFPiwsmx8b8k2SSSbzDWOfo3MoFdoIbyxuUGqQoouqFEa7qtOm88qRRffisj6_1j8mZpIP3Bb5WuVqTkwTdeg9nZF_qczXUjWNquXJ_LegqFFkXc0hNJ6xHaIuI6luJusNl2zKFGCstJURBpfS7DQzus7h2ka-ySU-FGre_LswPdI2H1lK0wJ0tsteZs2Rn45Qv2JbMHvNnl9k2_ge-0tRODwEPr9Z4kzQozI8cKJp5nQ4LwKK2j2mJiZPrOdXcgJMaQuOUgTitg_TiBopH3oOf9IFWe5_TpNJhyMAxNvJcYKEOe7TxXiFHFvKUXqnWGh5298t9tn12ferb-cix1gQHhWhQSilQh3B2hhl7U2MIHUVA3iEqTKd7mwovcSXGG0AHO6udtGCQ0AdMe2rN2x71s_gHePGBwBdKqu91Q1YJ50FH4zCz1EGVzC56uDWZwJyioNx026okwmUFkFpEyitKdjRusx8pN94MvfhCrc2D8VFuxGcgn1aJ-Mgog7uZtAvMY9GLQ61GVsX7O2I9_p3qiLCoaYq2PFKADaV_78tB0-35T17UdHtmOTVeMi2h7slfED1ZnAfkww_AMx3-JI
  priority: 102
  providerName: ProQuest
Title Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors
URI https://link.springer.com/article/10.1007/s12185-020-02951-5
https://www.ncbi.nlm.nih.gov/pubmed/32705572
https://www.proquest.com/docview/2580377361
https://www.proquest.com/docview/2427302296
Volume 114
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9QwFD64u7D4Il52tboOEXzTQJtLax5HmXVRdhFxYHwqTXLCDu5Oh52O-AP84Z5k2hlkVfChtDSXhnwnOSc9N4CXwVqiCqW504YOKCUWvAky51pZ0SjdOGmjRvf8ojybqg8zPeudwlaDtfugkkw79c7ZjbhR9CbO6YrJ4fUeHGg6u0dDrqkYb3UHVZ7SiuVGaK6JgfauMn_u43d2dEvGvKUfTWzn9D7c6-VFNt4A_ADu4OIhHJ73GvFH8DPm3nDo2fJqTeu_JRG4YzE4M4u_5LknAvtOpSl-J_XzLbn-pbIVI9pBft36eSA5lHUtwx_JLJa5y3lS5DCa9hitk9G2iEs6nfON4TiNlBHNzqnR-rq9WR3B9HTy5d0Z7zMrcEfiT8ellL4MaEwIRel0CFgoETw6AkfoRjXG566ghxCMR1rktrTBoCUYbYyvL49hf9Eu8Akw7TyiyqVRzqgKjS2sQee1pNeh8DaDYpjg2vVhx2P2i6t6FzA5glITKHUCpdYZvNq2WW6Cbvyz9smAW90vwFUt9JtcVpUsiwxebItp6cQJbhbYrqmOItmNZBhTZvB4g_f2c1LEMEOVyOD1QAC7zv8-lqf_V_0Z3BXRRib5Np7Afnezxuck5HR2BHvVrBrBwfj9148Tur-dXHz6PEqU_gtXFfmG
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgEXxJtAASPBCSziV4IPCCGg2tJuT620txC_xIp2s-xmedz5PfxGxk6yK1TRWw-RovgRx_PZM5PxzAA8C8YgKqSiVmlUUArPaB1ETpU0vJaqtsJEi-74sBgdy08TNdmCP4MvTDxWOeyJaaN2jY3_yF9x9ToXZSkK9nb-jcasUdG6OqTQ6GCx73_9QJVt-WbvA9L3Oee7H4_ej2ifVYBaZP0tFUK4InitQ2CFVSF4Jnlw3uLAuKplrV1uGd6EoJ1HgJvCBO0NfoKJseUF9nsJLiPjzaOyV07WCh4r85TQLNdcUYWsu3fS6Vz1kJdGX-gcr5jaXv3LCM9It2css4nh7d6A672kSt510LoJW352C66Me1v8bfgds35Y78j8ZIU7T4PCd0tiWGgSjQHUIbS_Y2mKHIr9fE1Oh6lsSRC1np42bhpQAiZtQ_zPdCCX2C_TZEIiSPAYJ5TghuznbbOg3ZF1HCnB1TLFRqvTZrG8A8cXMvt3YXvWzPx9IMo672UutLRall4bZrS3Tgl8HJgzGbBhgivbBzyPeTdOqk2o5kiUColSJaJUKoMX6zbzLtzHubV3BrpV_dJfVhugZvB0XYyLNk5wPfPNCutIlBpRetJFBvc6eq9fJ3gMcFTyDF4OANh0_v-xPDh_LE_g6uhofFAd7B3uP4RrPJ7MSR6VO7DdLlb-EYpWrXmc8Ezg80UvoL_x8DhW
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9QwFH4qU6nigthJKWAkOIHVxEuCDwgB7aildFQhKvUW4k2MaCfTmQzLnV_Fr-PZSWaEKnrrIVIUL3H8Pj8_520Az7zWiAohqZEKDyi5y2jleUql0KwSsjJcB43u4SjfOxYfTuTJGvzpfWGCWWXPEyOjtrUJ_8i3mXyV8qLgebbtO7OIo53hm-k5DRmkgqa1T6fRQuTA_fqBx7f56_0dpPVzxoa7n9_v0S7DADUoBjSUc25z75TyPsuN9N5lgnnrDA6SyUpUyqYmwxvvlXUIdp1rr5zGz9EhzjzHfq_BehFORQNYf7c7Ovq01GEUaUxvliomqcSNvHPZaR33cGcNntEpXiHRvfx3W7wg617Q08btb3gTbnRyK3nbAu0WrLnJbdg47DTzd-B3yAFinCXT0wXyoRpF8YaEINEkqAaoRaB_x9IYRxT7-RZdEGPZnCCGHT2r7dijPEyamrif0TyXmK_jqFAiSP4QNZQge3bTpp7R1oAdR0pw7Yyx0eKsns3vwvGVzP89GEzqiXsARBrrnEi5EkaJwimdaeWMlRwf-8zqBLJ-gkvThT8PWThOy1Xg5kCUEolSRqKUMoEXyzbTNvjHpbW3erqVHSOYlyvYJvB0WYxLOExwNXH1AusIlCFRllJ5Avdbei9fx1kId1SwBF72AFh1_v-xbF4-liewgYun_Lg_OngI11kw04nulVswaGYL9wjlrEY_7gBN4MtVr6G_os898Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Induced+pluripotent+stem+cell-derived+natural+killer+cells+gene-modified+to+express+chimeric+antigen+receptor-targeting+solid+tumors&rft.jtitle=International+journal+of+hematology&rft.au=Ueda%2C+Tatsuki&rft.au=Kaneko%2C+Shin&rft.date=2021-11-01&rft.pub=Springer+Singapore&rft.issn=0925-5710&rft.eissn=1865-3774&rft.volume=114&rft.issue=5&rft.spage=572&rft.epage=579&rft_id=info:doi/10.1007%2Fs12185-020-02951-5&rft.externalDocID=10_1007_s12185_020_02951_5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0925-5710&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0925-5710&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0925-5710&client=summon